Vista Pharmaceuticals Reports ₹12.06 Crore Net Loss in FY26, Faces Loan Defaults

Net Loss: ₹12.06 crore
Revenue from operations: ₹5.40 crore

Reader Takeaway: Consecutive losses and loan defaults signal high risk, warrant conversion of convertible warrants critical.

What just happened

Vista Pharmaceuticals Ltd has reported a net loss of ₹12.06 crore for the fiscal year ended March 31, 2026. This marks the fifth consecutive year the company has ended in the red. Revenue from operations for FY26 stood at ₹5.40 crore, a significant drop from ₹10.07 crore in FY25. The company also acknowledged defaults in the repayment of term loans to the Bank of Baroda.

Why this matters

The recurring losses, coupled with defaults on loan obligations and outstanding statutory liabilities, highlight severe financial distress. The company's own Board has flagged "material uncertainty" regarding its ability to continue as a going concern. While convertible warrants have been issued to raise capital, the financial health of Vista Pharmaceuticals remains a significant concern for shareholders.

The backstory

This is the fifth consecutive year Vista Pharmaceuticals has reported losses. The company has been struggling with profitability, and the situation has now escalated to loan defaults and the acknowledgment of going concern risks by its own board.

What changes now

The company has issued convertible share warrants to promoters and investors, receiving ₹3.08 crore as upfront consideration. Management expects these funds to improve liquidity. However, the ability to service existing debt and statutory dues remains critical.

Risks to watch

The primary risks include the company's going concern uncertainty, ongoing loan defaults, failure to address statutory liabilities (including Income Tax, Provident Fund, TDS, and ESI), and negative working capital. The significant impairment of ₹8.22 crore on trade receivables also points to collection challenges.

Peer comparison

[No peer comparison data available in the filing.]

Context metrics (time-bound)

Total Assets stood at ₹55.08 crore as of March 31, 2026. Total Equity was ₹36.44 crore, while Current Liabilities were ₹16.65 crore, resulting in negative working capital of ₹1.34 crore.

What to track next

Investors should closely monitor the conversion of the issued convertible warrants and the subsequent inflow of funds. Progress in regularizing loan repayments to Bank of Baroda and clearing outstanding statutory liabilities will be key indicators of the company's financial recovery.